Quest Diagnostics (NYSE:DGX) has been assigned a $113.00 price target by investment analysts at Mizuho in a research report issued to clients and investors on Wednesday. The brokerage currently has a “buy” rating on the medical research company’s stock. Mizuho’s price target points to a potential upside of 8.01% from the company’s previous close.
Other equities analysts have also recently issued reports about the stock. Canaccord Genuity lifted their price target on shares of Quest Diagnostics from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, October 26th. Goldman Sachs Group cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and reduced their price target for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. KeyCorp reissued a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. Zacks Investment Research raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, November 6th. Finally, ValuEngine cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the stock. Quest Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $106.95.
Shares of Quest Diagnostics (DGX) traded up $1.50 during midday trading on Wednesday, hitting $104.62. 890,897 shares of the stock were exchanged, compared to its average volume of 850,324. The company has a market capitalization of $14,260.00, a PE ratio of 21.80, a price-to-earnings-growth ratio of 2.04 and a beta of 0.60. Quest Diagnostics has a 52 week low of $90.10 and a 52 week high of $112.96. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78.
A number of hedge funds have recently modified their holdings of DGX. APG Asset Management N.V. increased its stake in Quest Diagnostics by 156.0% in the 3rd quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock valued at $251,320,000 after buying an additional 1,635,700 shares during the last quarter. Janus Henderson Group PLC increased its stake in Quest Diagnostics by 9,350.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,451,774 shares of the medical research company’s stock valued at $161,379,000 after buying an additional 1,436,412 shares during the last quarter. FMR LLC increased its stake in Quest Diagnostics by 62.2% in the 2nd quarter. FMR LLC now owns 1,232,272 shares of the medical research company’s stock valued at $136,978,000 after buying an additional 472,661 shares during the last quarter. Victory Capital Management Inc. increased its stake in Quest Diagnostics by 21.7% in the 3rd quarter. Victory Capital Management Inc. now owns 1,926,757 shares of the medical research company’s stock valued at $180,422,000 after buying an additional 343,399 shares during the last quarter. Finally, State Treasurer State of Michigan increased its stake in Quest Diagnostics by 598.9% in the 3rd quarter. State Treasurer State of Michigan now owns 314,263 shares of the medical research company’s stock valued at $29,428,000 after buying an additional 269,300 shares during the last quarter. Hedge funds and other institutional investors own 89.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Quest Diagnostics (DGX) Given a $113.00 Price Target at Mizuho” was reported by American Market News and is the property of of American Market News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/24/quest-diagnostics-dgx-given-a-113-00-price-target-at-mizuho.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
